CorEvitas
CorEvitas, a PPD/Thermo Fisher Scientific business unit, operates proprietary longitudinal clinical registries delivering regulatory-grade real-world evidence to pharmaceutical and biotech customers across six therapeutic areas, covering 500+ investigator sites and ~100,000 patients.
- Company typePrivate
- Founded2000
- HeadquartersWaltham, United States
- Headcount251–500
- GTM typeB2B
- OfferingServices
What CorEvitas does
CorEvitas operates as a branded real-world evidence (RWE) business unit within PPD, which is itself part of Thermo Fisher Scientific (NYSE: TMO). The company builds and operates proprietary longitudinal clinical registries that capture clinician- and patient-reported data from routine clinical practice across six therapeutic areas: dermatology, gastroenterology, neurology, obesity, pregnancy, and rheumatology. The portfolio is anchored by more than 20 years of continuous data collection, approximately 500 investigator sites globally, and a patient cohort of roughly 100,000, with newly launched registries in systemic lupus erythematosus (February 2025) and Alzheimer's disease (December 2025) extending the footprint. Acquired subsidiaries Vestrum Health (retina EHR analytics, 2021) and Pregistry (pregnancy safety studies, 2022), along with PPD CorEvitas Precision Medicine as a sub-brand, round out the product surface.
The underlying platform is a multi-disease registry network in which investigator sites contribute structured longitudinal data that can be aggregated, analyzed, and licensed to biopharmaceutical customers. CorEvitas generates revenue through subscription-based access to registry data, custom observational-study and RWE services (including pregnancy and lactation studies, health economics, and patient-centered research), and ongoing registry network participation fees. Pricing is enterprise and quote-based with annual billing cadence, and the go-to-market is direct enterprise sales conducted through PPD's global commercial organization, targeting pharmaceutical and biotech companies that need regulatory-grade evidence for drug development, post-authorization safety studies, and label-expansion submissions. The primary customer segment is pharma and biotech, with secondary segments in healthcare providers and government/public health agencies.
CorEvitas was originally established in 2000, was supported by an Audax Private Equity financing round in December 2019, and is now a wholly-owned subsidiary within Thermo Fisher Scientific following PPD's 2016 acquisition by Thermo Fisher. The company's geographic footprint is global, with active operations across North America, Europe (UK), and Asia-Pacific (China and Japan), and the recently launched international Alzheimer's registry indicates continued expansion beyond its historically US-anchored base.
CorEvitas firmographics
Firmographics- Name
- CorEvitas
- Legal name
- Thermo Fisher Scientific Inc.
- Website
- https://corevitas.com
- Company type
- Private
- Founded year
- 2000
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Short description
- CorEvitas, a PPD/Thermo Fisher Scientific business unit, operates proprietary longitudinal clinical registries delivering regulatory-grade real-world evidence to pharmaceutical and biotech customers across six therapeutic areas, covering 500+ investigator sites and ~100,000 patients.
- Ownership category
- akta.pro rank
CorEvitas industry classification
Industry- Product category
- Real-World Evidence & Clinical Registry Data Services
- NAICS
- Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)
- akta.pro primary industry
- Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG) (HLAGAAAJ)
- akta.pro secondary industry
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
Keywords
Where CorEvitas is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
CorEvitas business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Clinical Registry Data Access: Subscription-based access to proprietary longitudinal registry data for pharmaceutical and biotech companies conducting drug development, post-authorization safety studies, and real-world evidence generation.
- Observational Studies and RWE Services: Custom study design and real-world evidence generation services including pregnancy and lactation studies, health economics, and patient-centered research.
- Registry Network Participation: Engagement of investigator sites and physicians in registry networks, creating recurring data collection and study opportunities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Custom enterprise agreements based on data scope, therapeutic area, and study requirements |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
CorEvitas product offering
Product offeringCore offering
CorEvitas operates a portfolio of proprietary longitudinal clinical registries that collect regulator-grade clinician- and patient-reported real-world data across dermatology, gastroenterology, neurology, obesity, pregnancy, and rheumatology therapeutic areas. It sells subscription-based access to this registry data and delivers custom observational studies, post-authorization safety studies, pregnancy and lactation research, and patient-centered evidence services to pharmaceutical and biotech customers. Supporting offerings include precision medicine real-world data and retina EHR analytics via the acquired Vestrum Health platform.
Product overview
CorEvitas (operating as PPD CorEvitas under Thermo Fisher Scientific) is a multi-product platform offering proprietary longitudinal clinical registries. The core offering is the PPD CorEvitas Clinical Registries platform with over 20 years of proprietary data collection, which includes disease-specific registries across Dermatology, Gastroenterology, Neurology, Obesity, Pregnancy, and Rheumatology. The portfolio includes acquired brands such as Vestrum Health (retina EHR data analytics) and Pregistry (pregnancy safety studies). Additional offerings include PPD CorEvitas Precision Medicine for targeted therapeutic approaches. Together, these products enable regulatory-grade real-world evidence generation for pharmaceutical and biotech companies.
Differentiator
Problem solved
Functional benefit
Brands
- PPD CorEvitas Clinical Registries: Proprietary real-world data registries covering dermatology, gastroenterology, neurology, obesity, pregnancy, and rheumatology therapeutic areas
Products and services
- PPD CorEvitas Clinical Registries
Quantifiable outcome
- 500+ investigator sites and 100,000 patients across registry portfolio
- +1 more outcomes
Companies that use CorEvitas
Customer profileSegments3 records
Ideal customer profiles3 records
CorEvitas technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
CorEvitas partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Thermo Fisher ScientificcoreCorEvitas operates as a subsidiary/business unit within PPD, which is part of Thermo Fisher Scientific. The integration provides access to Thermo Fisher's full-service clinical research organization capabilities, laboratory services, and global infrastructure.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
CorEvitas competitors and assessment
Company assessmentDirect peers
- IQVIA: Largest global CRO and real-world evidence provider, offering proprietary datasets, observational studies and analytics services to biopharma. Overlaps directly with CorEvitas in registry-based RWE and longitudinal clinical data.
- Flatiron Health: Oncology-focused real-world evidence company (acquired by Roche) that aggregates EHR data from oncology practices. Comparable as a longitudinal disease-specific RWE platform serving biopharma for drug development and regulatory submissions.
- Health Catalyst: Healthcare data and analytics platform providing real-world data infrastructure and analytics to providers, payers and life sciences. Comparable in selling longitudinal clinical data assets to biopharma.
- Parexel International: Global CRO with established real-world evidence, post-marketing and observational research capabilities. Comparable business model and biopharma customer base to CorEvitas.
- ICON plc: Major global CRO with real-world evidence and late-phase research capabilities post-PRA Health Sciences acquisition. Competes directly for biophara real-world data and post-authorization study contracts.
- Syneos Health: Biopharma solutions organization offering clinical development and real-world evidence services. Directly competes for biopharma RWE and observational study engagements.
Others
- Veradigm (formerly Allscripts): EHR vendor with real-world data offerings derived from its installed provider base. Not a direct CRO competitor but a data infrastructure peer whose EHR-extracted datasets compete for the same RWE buyer budgets.
Broad incumbents
- Cognizant (TriZetto / RWE Services): Large IT services firm with healthcare data, real-world evidence and life sciences analytics offerings. Competes for biopharma RWE and clinical data engagements, particularly with payer and provider data sources.
- Optum (UnitedHealth Group): Massive healthcare data and analytics business combining claims, EHR and pharmacy data. Broad incumbent offering real-world evidence at greater scale than CorEvitas, often competing for the same biopharma RWE budget.
- Medidata Solutions (Dassault Systèmes): Clinical trial technology and data platform serving biopharma with trial data capture, analytics and real-world data capabilities. Adjacent offering set to CorEvitas registries within the same sponsor buyer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
CorEvitas social profiles
Digital presenceCorEvitas financial estimates
Financial estimateRevenue estimate
Valuation estimate
CorEvitas leadership team
Management profileNumber of profiles
Profiles11 records
CorEvitas subsidiaries and ownership
Company hierarchySubsidiaries2 records
CorEvitas funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
CorEvitas M&A and investment
M&A and investmentM&A4 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about CorEvitas
What does CorEvitas do?
CorEvitas operates a portfolio of proprietary longitudinal clinical registries that collect regulator-grade clinician- and patient-reported real-world data across dermatology, gastroenterology, neurology, obesity, pregnancy, and rheumatology therapeutic areas. It sells subscription-based access to this registry data and delivers custom observational studies, post-authorization safety studies, pregnancy and lactation research, and patient-centered evidence services to pharmaceutical and biotech customers. Supporting offerings include precision medicine real-world data and retina EHR analytics via the acquired Vestrum Health platform.
Is CorEvitas a public or private company?
CorEvitas is a private company. It is classified as corporate owned and is currently operating.
When was CorEvitas founded?
CorEvitas was founded in 2000. It employs 251 to 500 people.
Where is CorEvitas based?
CorEvitas is headquartered in Waltham, United States, in the North America region.
How does CorEvitas make money?
Three revenue lines are on record. Clinical Registry Data Access are the primary driver. The others are observational Studies and RWE Services and registry Network Participation.
Who are CorEvitas's main competitors?
Direct peers on record are IQVIA, Flatiron Health, Health Catalyst, Parexel International, ICON plc and Syneos Health. Veradigm (formerly Allscripts) is listed as an others. Broad incumbents are Cognizant (TriZetto / RWE Services), Optum (UnitedHealth Group) and Medidata Solutions (Dassault Systèmes).
Does CorEvitas have an API?
No public API is recorded for CorEvitas.
What industry is CorEvitas in?
CorEvitas's product category is Real-World Evidence & Clinical Registry Data Services. Its primary akta.pro industry code is HLAGAAAJ, Imaging & Cardiac Safety Core Labs (ECOG/EEG/ECG), with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 54169 and its SIC code is 8000.